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Background: Salivary gland tumors are a rare and morphologically diverse group of lesions and their frequency is 
still unknown in several parts of the world. The knowledge of its population characteristics contributes to a better 
understanding of its etiopathogenesis. Objectives: This study investigated the frequency of salivary gland tumors 
in a region of southern Brazil and compared these data in a literature review. 
Material and Methods: A retrospective study was conducted of salivary gland tumors diagnosed at two pathology 
centers from 1995 to 2016. Patient age and gender, tumor site and frequency, histopathological diagnosis, and 
symptomatology were evaluated. Chi-squared tests were used to assess the associations between variables. To 
compare our data, we also conducted a literature review of publications in the PubMed and LILACS databases of 
retrospective studies of salivary gland tumors. 
Results: A total of 124 salivary gland tumor cases was identified, 81 (65.3%) of which were classified as benign 
and 43 (34.6%) as malignant. Most tumors occurred in the parotid gland (57.2%). Pleomorphic adenoma was the 
most common tumor (59.6%), followed by adenocarcinoma not otherwise specified (8.8%). The tumors occurred 
more often in women (54.8%) than in men (45.2%). Malignant tumors were associated with pain in 31.4% of cases 
(p <0.05). The literature review included 35 articles from different countries. Women were most affected, with a 
mean age of 41.7 years. The most common benign tumor was pleomorphic adenoma (48.2%) and the most common 
malignant tumor was mucoepidermoid carcinoma (8.7%). 
Conclusions: The results of the present study showed that salivary gland tumors are rare. The parotid gland is the 
most common location and pleomorphic adenoma are the most frequent lesions. The malignant tumors presented 
as several histological types and the incidence was variable globally.
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Introduction
A variety of tumors can develop in the salivary glands. 
Currently recognized 10 subtypes of benign and 20 sub-
types of malignant salivary gland tumors (SGT) (1). 
However, SGT are rare, representing less than 3% all 
head and neck tumors (2). The majority of SGT are be-
nign, with pleomorphic adenoma (PA) the most com-
mon. Among malignant tumors, mucoepidermoid carci-
noma (MEC) and cystic adenoid carcinoma (ACC) are 
more common (2). 
Epidemiological studies across the world have shown 
differences in the incidence and distributions of SGT, 
with diverse demographic results in different regions (3-
4). However, there are few studies about the incidence 
in the Brazilian population, especially considering its 
geographical size (2,5-9). 
Therefore, the aim of the present study was to investiga-
te the pattern of the occurrence of SGT diagnosed in two 
diagnostic services that are references to the Santa Cata-
rina State, Brazil and to compare the incidence findings 
with those available from other places around the world 
through a literature review. 
Material and Methods
-Retrospective study  
The samples included this study were selected from 
histopathological reports of the Pathological Anatomy 
Service and the Oral Pathology Laboratory, two diag-
nostic services at Federal University of Santa Catarina. 
All cases of SGT diagnosed between 1995 and 2016 
were selected. Slides stained with hematoxylin and eo-
sin (H&E) were analyzed by light microscopy (Olympus 
Corporation, Tokyo, Japan) and classified according to 
their histopathological characteristics. This study was 
approved by the University’s Human Research, Ethical 
Committee (number 1.657.413).
Clinical data were collected from biopsy reports from 
both pathological services as well as from the university 
hospital records. The patient information included age 
and gender. Lesion-related data included histological 
types, anatomic sites, and symptomatology. Data were 
collected and stored in a Microsoft Excel® (Microsoft 
Corporation, Redmond, USA) spreadsheet. Statistical 
analysis was performed with all collected data using 
the chi-squared test in the SPSS statistics software to 
analyze associations between the variables of interest 
(age, gender, histological diagnoses, and symptoms. The 
statistical significance was set at α = 0.05.
-Literature review
A review of the literature with no restriction on publi-
cation year was carried out to retrieve studies about 
SGT. The inclusion criteria were retrospective and case 
series studies without restriction on SGT site or his-
tological type. The exclusion criteria were studies in 
languages other than English, Portuguese, or Spanish, 
studies without available full texts and not indexed for 
PubMed-Medline. An electronic search was performed 
in the Latin America and Caribbean Health Sciences 
(LILACS) and PubMed (including MEDLINE) data-
bases on February 2018. The following combinations 
of keywords were used in the search: “Salivary Gland 
Neoplasms” OR “Cancer of the Salivary Gland” OR 
“Salivary Gland Cancer” OR “Salivary gland diseases” 
OR “Salivary gland tumours” OR “Salivary gland tu-
mors” AND “Retrospective study. All references were 
managed, and duplicate hits were removed by referen-
ce manager software (Endnote X7, Thompson Reuters, 
New York, New York, USA). The selection of the stu-
dies was performed in two phases. In phase 1, titles and 
abstracts that met the eligibility criteria were selected. 
If either provided insufficient information for a decision 
on inclusion/exclusion, the full text was obtained and as-




The Pathological Anatomy Service received 126,508 
cases for diagnosis between 1995-2016, 103 of which 
were diagnosed as SGT (0.08%). The Oral Pathology 
Laboratory received 2,703 cases between 2006-2016, 
21 of which were diagnosed as SGT (0.77%). In total, 
124 SGT were identified in the two pathology servi-
ces during the 21-year period. Of the 124 tumors, 81 
(65.3%) were benign and 43 (34.6%) were malignant. 
Of the benign tumors, pleomorphic adenoma (PA) was 
the most common (91.3%). Of the malignant tumors, 
adenocarcinoma not otherwise specified (NOS) was the 
most common (25.5%), followed by ACC, MEC, and 
carcinoma ex pleomorphic adenoma (Ex-PA) (8 cases 
each, 18.6%). Table 1 shows the relative frequencies of 
the 124 tumors. The histological characteristics of the le-
sions most prevalent in this study are shown in figure 1. 
The most common site was the parotid gland (57.2%), 
followed by the minor (29%), submandibular (11.2%), 
and sublingual glands (2.41%). Regarding the benign 
tumors, 48 occurred in the parotid gland, 22 in the minor 
salivary glands, and 11 in the submandibular gland, whi-
le 23, 14, and three malignant tumors were identified in 
the same locations, respectively. Only malignant tumors 
affected the sublingual glands, with three cases. Among 
the minor SGT, the palate was the most common site, 
accounting for 17.7% of all cases, followed by the lip 
(5.6%) (Table 2). 
Information on symptoms was present for 60 cases of 
benign tumors; of these, 13 presented pain (21.6%) 
and one with facial paralysis (1.6%). Among malignant 
tumors, information was available for 35 cases, 11 of 
which presented pain (31.4%) and two presented facial 
paralysis (5.7%). The remaining cases had no symp-
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Pleomorphic Adenoma 74 31 43 40.4 16 - 76
Warthin Tumour 4 2 2 58.3 47 - 67
Myoepithelioma 2 2 0 40.5 25 - 56
Oncocytoma 1 0 1 63 -----
MALIGNANT
Adenocarcinoma NOS 11 6 5 56.5 30 - 94
Adenoid Cystic Carcinoma 8 4 4 54.3 32 - 75
Mucoepidermoid Carcinoma 8 3 5 45.1 14 - 85
Carcinoma Ex-Pleomorphic Adenoma 8 5 3 53 29 - 85
Myoephitelial Carcinoma 2 1 1 69.5 64 - 75
Clear Cell Carcinoma 2 1 1 59 46 - 72
Polymorphous Adenocarcinoma 1 0 1 57 -----
Salivary Duct Carcinoma 1 1 0 72 -----
Acinic Cell Carcinoma 1 0 1 NS* -----
Lymphoepithelial Carcinoma 1 0 1 22 -----
Table 1: Comparative incidence, gender, and mean age distributions according to the histological subtypes of 81 benign and 43 malig-
nant salivary gland tumors.
*NS = not stated.  Male 56 (45.2%) / Female 68 (54.8%).  
toms. The chi-square test showed a significant associa-
tion between malignant tumors and pain (p = 0.04).
Patient age was available in 117 cases. The ages ranged 
from 14 to 94 years (Table 1). Among benign tumors, the 
average was 41.3 years, with the highest prevalence in 
the third decade. Among malignant tumors, the patient 
average was 54.3 years, with a higher prevalence in the 
fifth decade. The difference in the numbers of patients 
with benign and malignant tumors was not statistically 
significant (p = 0.13). 
Regarding the distributions by gender, 54.8% and 45.2% 
of all neoplasms occurred in women and men, respecti-
vely (p = 0.13). Among benign tumors, 56.7% occurred 
in women and 43.2% in men (p = 0.27). Among malig-
nant tumors, 51.1% occurred in women and 48.8% in 
men (p = 0.12) (Table 1). 
-Literature Review
The literature review yielded 907 citations from the 
electronic databases. The inclusion and exclusion cri-
teria were applied during a comprehensive evaluation 
of titles and abstracts, resulting in the selection of 35 
studies for full-text review. Based on these studies, the 
global incidence of SGT was estimated. Fifteen studies 
were conducted in Asia, eight in Africa, eight in Ameri-
ca, three in Europe, and there was one multicenter study 
in Europe and Asia. 
The incidence of salivary gland tumors is higher in wo-
men (55.4%) than that in men (47.2%). Considering 
only the studies that were performed in adults, the mean 
ages of patients with benign and malignant tumors were 
43.3 and 51 years, respectively. Benign tumors (61.9%) 
were more prevalent than malignant tumors (22.4%), 
and PA had the highest incidence (48.2%).
Tumors were more common in the major salivary glands 
(73.2%), especially the parotid gland (58.2%). The mi-
nor salivary glands were involved in 24.8% of the cases, 
most commonly the palate (24.5%). The incidence of the 
tumors is summarized in table 3, 3 continue. 
Discussion
During this 21-year study, SGT were found in patients 
between the ages of 14 to 94 years (mean 43.3). In the 
current study, patients with benign tumors generally 
were younger (mean 41.3 years) than patients with ma-
lignant tumors (mean 54.3 years). Our data were very 
similar to those in other studies in Brazil (2,7). The ove-
rall mean ages in our review were 43.3 and 51 years for 
benign and malignant tumors, respectively. Studies from 
Africa reported lower mean ages of impairment (less 
than 40 years), suggesting that factors such as low life 
expectancy and lack of prevention measures may contri-
bute to this index (10-11).
SGT were more common in women (54.8%) than in men 
(45.2%). However, the distribution of malignant tumors 
was similar between women and men. Most studies have 
shown that SGT are more common in women than men, 
with an average of 55.4% (4,12-14). In contrast, some 
studies have reported a predominance of SGT in men 
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Fig. 1: A: Pleomorphic adenoma: (H&E 100x) Tumor composed of epithelial and myoepithelial cells arranged in di-
verse patterns, surrounded by a fibrous capsule. B: Pleomorphic adenoma: (H&E 400x) Plasmacytoid myoepithelial 
cells and ductal structures in a fibrous stroma. C: Adenocarcinoma NOS: (H&E 200x) Several cell types, including 
clear, mucous, and epidermoid cells arranged in different shapes, showing intense cellular and nuclear pleomor-
phisms. D: Cystic adenoid carcinoma: (H&E 200x) Islands of basaloid epithelial cells containing multiple cylin-
drical spaces such as cystic spaces filled with basophilic mucoid material. E: Mucoepidermoid carcinoma: (H&E 
200x) Nests of pleomorphic epidermoid cells and mucous-producing cells surrounding cystic spaces. F: Carcinoma 
ex-pleomorphic adenoma: (H&E 200x) Epithelial cells with pleomorphic nuclei arranged in the islands and ductal 
structures associated with suggestive pleomorphic adenoma areas.
(15). Two large studies from China has shown that be-
nign tumors are more common in women, while malig-
nant tumors are more common in men (16,17). 
In the present study, benign tumors were more common 
than malignant ones, with frequencies of 65.3% and 
34.6%, respectively. This result is similar to the rates 
reported by studies from China (3,18), India (19), and 
Mexico (20), suggesting that benign tumors are predo-
minant in SGT worldwide. Brazilian studies reported 
averages of 80% benign tumors and 20% malignant tu-
mors (7-9). However, in the literature review, the global 
incidence was 61.9% for benign tumors and 22.4% for 
malignant tumors. In general, there appear to be geogra-
phical variables and the proportions of benign/malignant 
tumors can be variable. As expected, studies from hos-
pitals reference in oncology report balanced frequency 
of malignant and benign tumors or more frequency of 
malignant tumors (21,22). 
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TUMORS Major salivary glands Minor salivary glands Total (%) 
Parotid Submandibular Sublingual Palate Buccal Oropharynx Lip Retromolar 
region 
BENIGN 
Pleomorphic adenoma 43 10 0 15 1 1 4 0 74 
Warthin Tumour 4 0 0 0 0 0 0 0 4 
Myoepithelioma 1 0 0 1 0 0 0 0 2 
Oncocytoma 0 1 0 0 0 0 0 0 1 
MALIGNANT 
Adenocarcinoma NOS 11 0 0 0 0 0 0 0 11 
Adenoid cystic carcinoma 2 0 2 3 0 0 1 0 8 
Mucoepidermoid 
carcinoma 
2 0 1 2 0 1 0 2 8 
Carcinoma ex-pleomorphic 
adenoma 
3 2 0 0 1 0 1 1 8 
Myoephitelial carcinoma 0 1 0 1 0 0 0 0 2 
Clear cell carcinoma 1 0 0 0 0 0 1 0 2 
Polymorphous 
adenocarcinoma 
1 0 0 0 0 0 0 0 1 
Salivary duct carcinoma 1 0 0 0 0 0 0 0 1 
Acinic cell carcinoma 1 0 0 0 0 0 0 0 1 
Lymphoepithelial 
carcinoma 
1 0 0 0 0 0 0 0 1 
	
Table 2: Histological classifications and sites of benign and malignant salivary gland tumors. 
 
AUTHORS Country Years N Benign Malignant Others 
PA WT MEP NOS ACC MEC EX-
PA 
Al-Khateeb et al., 
2007 (30) 
Jordan 11 102 55 4 4 1 13 8 1 16 
Ansari et al., 
2007 (12) 
Iran 20 130 85 - - 19 3 15 1 7 
Araya et al., 2015 
(29) 
Chile 11 279 150 23 1 13 12 16 4 60 




10 2218 1099 547 55 22 102 91 24 278 




10 282 206 - - 11 25 12 1 27 
Fang et al., 2013 
(33) 
China 25 122 96 1 5 - 2 8 - 10 
Fonseca et al., 
2012 (5) 
Brazil 10 493 314 36 3 33 22 39 8 38 
Gao et al., 2017 
(3) 
China 50 7190 3062 937 118 214 733 751 210 1165 
Ito et al., 2005 (2) Brazil 29 496 269 42 6 7 33 67 3 63 
Jaafari-
Ashkavandi et al., 
2013 (28) 
Iran 5 366 199 26 17 1 55 36 3 29 
Kasangaki & 
Kamulegeya, 
2004  (11) 
Uganda 12 142 60 - - 15 18 8 2 103 
Kara et al., 2010 
(15) 
Turkey 21 125 80 6 2 5 11 3 2 16 
Laikui et al., 2008 
(32) 
China 12 79 52 - 8 2 1 13 - 3 
Laishram et al., 
2013 (14) 
India 9 104 43 8 3 - 4 7 2 37 
Li et al., 2007 (17) China 47 3461 1776 151 3 228 252 261 145 645 
Luksic et al., 
2012 (25) 
Croatia 25 779 368 87 10 17 91 64 32 110 
Ma’aita et al., 
1999 (26) 
Jordan 9 221 139 11 - 8 12 38 - 13 
Masanja et al., 
2003 (21) 
Tanzania 19 153 68 - - 10 38 15 - 22 
Mejía-Velázquaz 
et al., 2012 (20) 
Mexico 8 360 236 20 4 - 18 17 7 58 
Morais et al., 
2011 (6) 
Brazil 16 303 171 16 1 10 16 42 2 45 
Nepal et al., 2010 
(23) 
Nepal 5 51 39 2 - - 4 3 2 1 
Ochicha et al., 
2009 (36) 
Nigeria 8 78 38 - 1 - 3 18 - 18 
Oliveira et al., 
2009 (7) 
Brazil 10 599 406 38 - 37 39 30 - 99 
Saghravanian et 
al., 2013 (4) 
Iran 38 165 77 1 4 12 23 33 2 13 
Sando et al., 2016 
(10) 
Cameroon 11 275 132 2 1 11 18 13 - 98 
Shishegar et al., 
2011 (37) 
Iran 5 392 227 23 12 5 50 30 2 43 
Subhashraj, 2008 
(19) 
India 15 684 363 21 1 31 66 49 24 129 
Taghavi et al., 
2016 (22) 
Iran 15 184 60 1 3 11 41 50 5 13 
Tian et al., 2010 
(18) 
China 23 6982 3281 961 174 118 594 588 169 1097 
Table 3: Comparative prevalence of benign and malignant salivary gland tumors in published studies.
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AUTHORS Country Years N Benign Malignant Others 
PA WT MEP NOS ACC MEC EX-
PA 
Al-Khateeb et al., 
2007 (30) 
Jordan 11 102 55 4 4 1 13 8 1 16 
Ansari et al., 
2007 (12) 
Iran 20 130 85 - - 19 3 15 1 7 
Araya et al., 2015 
(29) 
Chile 11 279 150 23 1 13 12 16 4 60 
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10 282 206 - - 11 25 12 1 27 
Fang et al., 2013 
(33) 
China 25 122 96 1 5 - 2 8 - 10 
Fonseca et al., 
2012 (5) 
Brazil 10 493 314 36 3 33 22 39 8 38 
Gao et al., 2017 
(3) 
China 50 7190 3062 937 118 214 733 751 210 1165 
Ito et al., 2005 (2) Brazil 29 496 269 42 6 7 33 67 3 63 
Jaafari-
Ashkavandi et al., 
2013 (28) 
Iran 5 366 199 26 17 1 55 36 3 29 
Kasangaki & 
Kamulegeya, 
2004  (11) 
Uganda 12 142 60 - - 15 18 8 2 103 
Kara et al., 2010 
(15) 
Turkey 21 125 80 6 2 5 11 3 2 16 
Laikui et al., 2008 
(32) 
China 12 79 52 - 8 2 1 13 - 3 
Laishram et al., 
2013 (14) 
India 9 104 43 8 3 - 4 7 2 37 
Li et al., 2007 (17) China 47 3461 1776 151 3 228 252 261 145 645 
Luksic et al., 
2012 (25) 
Croatia 25 779 368 87 10 17 91 64 32 110 
Ma’aita et al., 
1999 (26) 
Jordan 9 221 139 11 - 8 12 38 - 13 
Masanja et al., 
2003 (21) 
Tanzania 19 153 68 - - 10 38 15 - 22 
Mejía-Velázquaz 
et al., 2012 (20) 
Mexico 8 360 236 20 4 - 18 17 7 58 
Morais et al., 
2011 (6) 
Brazil 16 303 171 16 1 10 16 42 2 45 
Nepal et al., 2010 
(23) 
Nepal 5 51 39 2 - - 4 3 2 1 
Ochicha et al., 
2009 (36) 
Nigeria 8 78 38 - 1 - 3 18 - 18 
Oliveira et al., 
2009 (7) 
Brazil 10 599 406 38 - 37 39 30 - 99 
Saghravanian et 
al., 2013 (4) 
Iran 38 165 77 1 4 12 23 33 2 13 
Sando et al., 2016 
(10) 
Cameroon 11 275 132 2 1 11 18 13 - 98 
Shishegar et al., 
2011 (37) 
Iran 5 392 227 23 12 5 50 30 2 43 
Subhashraj, 2008 
(19) 
India 15 684 363 21 1 31 66 49 24 129 
Taghavi et al., 
2016 (22) 
Iran 15 184 60 1 3 11 41 50 5 13 
Tian et al., 2010 
(18) 
China 23 6982 3281 961 174 118 594 588 169 1097 
Tilakaratne et al., 
2009 (34) 
Sri-Lanka 17 713 274 29 8 13 96 154 23 116 
Trenkic 
Bozinovic et al., 
2015 (27) 
Serbia 2 139 50 48 2 - 5 12 6 16 
Vargas et al., 
2002 (8) 
Brazil 23 124 84 13 1 1 5 13 3 4 
Vasconcelos et 
al., 2016 (9) 
Brazil 15 109 69 16 - - 14 5 - 5 
Wang et al., 2015 
(16) 
China 10 2508 1032 471 192 23 120 160 26 484 
Zaman et al., 
2014 (31) 
Pakistan 2 91 43 - 3 - 16 15 1 13 
Present study Brazil 21 124 74 4 2 11 8 8 8 9 
Total - - 30.623 14.777 3.545 644 889 2.563 2.692 718 4.903 
% all tumors - - - 48.2 11.5 2.0 2.9 8.3 8.7 2.3 16 
	
Table 3 continue: Comparative prevalence of benign and malignant salivary gland tumors in published studies.
PA – pleomorphic adenoma; WT – warthin tumour; MEP – mioephitelyoma; NOS – adenocarcinoma not otherwise specified; ACC – adenoid 
cystic carcinoma; MEC – mucoepidermoid carcinoma; Ex-PA – carcinoma ex-pleomorphic adenoma. 
The majority of SGT occurred in major salivary glands 
(70%), especially in the parotid gland, similar to average 
found in the literature (73,2%). Several large series, es-
pecially in Asian countries, have shown similar distribu-
tion, with more frequency in the parotid, followed by the 
minor and submandibular gland (3,18,23). Other studies 
have a higher distribution in submandibular glands than 
in minor salivary glands (8,12). 
The sublingual gland is rarely affected. In the present 
survey, only three cases were recorded in this location; 
all were malignant, with two ACC and one MEC. The 
classification of head and neck tumors of World Heal-
th Organization (2005) shows that 70-90% of tumors in 
sublingual glands are malignant (24). Other studies have 
also reported a low prevalence and a predominance of 
malignant tumors in the sublingual glands (16,22,25). 
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Although most SGT occur in the major salivary glands, 
the preferred localization of MEC in the present study 
was the minor salivary glands, contrary to previous stu-
dies (6,17,25). ACC occurred in equal frequencies in the 
major and minor glands. However, some studies have 
shown ACC to be more common in the minor salivary 
glands than in the submandibular and parotid glands 
(2,3,18,26,27). 
Considering only the minor salivary glands, the palate 
was the most frequent location for both benign and ma-
lignant tumors. The literature data corroborate this fin-
ding (19,28-31). All the studies in the literature review 
reported the palate to be a common intraoral site. In the 
present survey, the retromolar region was affected only 
by malignant tumors. Other studies also show a predo-
minance of malignant tumors in this region (3,32). 
PA was the most common tumor (59.6%) of all salivary 
tumors, accounting for 91.3% of benign tumors in the 
present study. The frequency of PA among all SGT in 
the literature ranged from 32.6 to 78.6% (22,33). The 
average in our literature review was 48.2%. The se-
cond most common benign tumor was Warthin’s tumor 
(4.9%). This agrees with previously published reports, 
in which the incidence was similar (5% and 4.1%) (19, 
34). However, its frequency varies between studies, ran-
ging from 0.5% to 18% of all tumors (18,22). The avera-
ge in our literature review was 11.2%. 
Among malignant tumors, adenocarcinoma NOS was 
the most frequent (25%). The most common location of 
this tumor, as demonstrated in this study, it is the parotid 
gland, which is involved in more than 50% of cases (3). 
In addition, their frequency varies greatly in the literatu-
re, due to complex definition. However, it is not usually 
the most frequent tumor, as demonstrated by our litera-
ture review, in which adenocarcinoma NOS comprised 
only 2.9% of all cases (12,17,25). 
In this study, MEC, ACC, and Ex-PA presented at the 
same frequencies. However, in our literature review, 
they presented at frequencies of 8.7%, 8.3%, and 2.3%, 
respectively. The frequency of Ex-PA in the literature is 
lower than that in our study, showing indexes of about 
0.4 to 10% (13,17,20,35). Considering only malignant 
lesions, some studies reported MEC to be most common 
(5,26,36), while others reported ACC to be the most pre-
valent (13,21,27,37). 
The most significant sign of benign SGT is a painless 
swelling. Pain, rapid growth, and an ulcerative surface 
are noted in malignant cases and especially high-grade 
tumor (22). In this study, 21.6% of patients with benign 
tumors reported pain and one patient reported facial ner-
ve paralysis. Among patients with malignant tumors, 
31.4% reported pain and 5.7% reported facial nerve pa-
ralysis. The pain was significantly more present in ma-
lignant tumors (p <0.05). This finding agrees with that 
of Comoglu et al., 2018, who showed that all patients 
with SGT with preoperative facial paralysis were diag-
nosed with malignant tumors, suggesting that this sign is 
indicative of malignancy (38). However, another study 
reported that three patients with benign tumors presen-
ted preoperative facial paralysis due to the compression 
caused by the lesion; therefore, this symptom should not 
be considered a sign of malignancy (39). 
Studying SGT is difficult because they are a large and 
diverse group of lesions characterized by morphologi-
cal heterogeneity (1). Moreover, studies on the relative 
frequencies of SGT from different parts of the world are 
difficult to compare because many are based on outdated 
classification, the number of cases is often small, and the 
origin of the study differ (medical or dental centers); in 
addition, the morphological criteria for various histopa-
thological diagnoses vary by pathologist, due in part to 
their individual training and experience (17,25). 
Conclusions
In summary, the results of the present study suggest that 
benign tumors are most common, especially in paro-
tid glands, and are represented mainly by PA. Women 
are the most often affected sex, especially for benign 
lesions. Regarding malignant tumors, the incidence by 
gender was variable, as was the incidence of several 
types worldwide. The findings of this study contribute 
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